uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients

uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients

Background Emerging evidence has highlighted the importance of extracellular vesicle (EV)-based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic melanoma. Considering the tumor-promoting implications of urokinase-type plasminogen activator receptor (uPAR) signaling,...

Full description

Bibliographic Details
Main Authors: Michele Guida, Letizia Porcelli, Simona De Summa, Roberta Di Fonte, Ivana De Risi, Marianna Garofoli, Mariapia Caputo, Antonio Negri, Sabino Strippoli, Simona Serratì, Amalia Azzariti
Format: Article
Language:English
Published: BMJ Publishing Group 2021-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/5/e002372.full

Internet

https://jitc.bmj.com/content/9/5/e002372.full

Similar Items